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Drug delivery from a Dry Powder Inhaler (DPI) is dependent on the peak inspiratory flow rate (PIFR) generated. Currently
available methods for estimating PIFR from most DPIs are limited and mainly rely on subjective assessment. We aim to
show that spirometric and Diskus™ PIFR and Inspiratory Vital Capacity (IVC) are related to the underlying respiratory
condition and that spirometric PIFR can be used to assess whether Diskus™ PIFR will be adequate when using this DPI.
Healthy volunteers and patients with asthma, COPD, neuromuscular disease and non-respiratory disorders were
recruited (n = 85). Demographics and baseline lung function by spirometry were recorded. Flow and volume readings
were taken while patients used a Diskus™ DPI, housed in an airtight container connected to a spirometer. T-tests
were performed to compare mean spirometric and Diskus™ PIFR/ IVC between groups. Stepwise regression analysis
of Diskus™ PIFR versus spirometric PIFR, spirometric IVC, age, gender, condition, BMI, FEV1 and FVC was performed.
The Diskus™ PIFR for the COPD and Neuromuscular Disease group was more than 10 L/min lower than the Healthy
or Asthma groups (p < 0.05). The mean spirometric and Diskus™ IVC of the Healthy group was significantly (>0.75 L)
higher than the mean for the other three groups (p < 0.05). Diskus™ PIFR was moderately correlated with spirometric
PIFR and age (Adjusted R2 = 0.58, p < 0.0001). PIFR generated using a Diskus™ DPI is dependent on the underlying
disease and age. A spirometric PIFR of less than 196 L/min should prompt further investigation into the suitability of a
patient for a Diskus™ DPI, with possible consideration of alternate devices.
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Inhaled bronchodilators and steroids have been the main-
stay of treatment of obstructive airways disease for at least
20 years (Hanania et al. 2012). There has also been a move
away from metered dose inhalers (MDIs) towards dry
powder inhalers (DPIs) to address the problem of poor co-
ordination that patients face with MDI use. Drug delivery
from a DPI is largely dependent on the flow rate generated
by the individual (Martonen & Katz 1993). These devices
usually have higher resistances that MDIs and a flow rate* Correspondence: jansenseheult@rcsi.ie
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in any medium, provided the original work is pgreater than 60 L/min is necessary to de-aggregate the
drug formulation into small particles that can travel to the
smaller airways (Burnell et al. 2001; Ganderton 1997),.
Therefore, patients’ ability to generate a sufficient peak in-
halation flow rate (PIFR) through the device to overcome
its resistance is a critical component of a successful in-
haler technique for most DPIs.
Janssens et al. (Janssens et al. 2008) and Jarvis et al. (Jarvis
et al. 2007) showed that flow rate was very dependent on
age in COPD patients; in elderly patients, the ability to
generate sufficient inspiratory flow across a dry powder
inhaler is compromised, irrespective of the presence of
chronic obstructive pulmonary disease. Plavec et al. inves-
tigated the proportion of patients with asthma or chronic
obstructive pulmonary disease (COPD) with significantan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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necessary for the adequate use of dry powder inhaler
(DPI) devices Diskus™ and Turbuhaler. They found that
significant proportions of patients with both asthma and
COPD failed to achieve an appropriate flow rate for drug
delivery and the proportion of patients who could not
generate a high flow rate increased during exacerbations
(Plavec et al. 2012). Another study done by Al-Showair
et al. also found that PIF from a Diskus™ inhaler was af-
fected by the severity of COPD; however, there were small
but significant improvements in the PIF achieved by some
patients after training (Al-Showair et al. 2007).
Identification of patients who are likely to achieve a sub-
optimal PIFR from any DPI is important as a low PIFR
can reduce the Fine Particle Dose delivered by more than
50%. Currently, the only available method of determining
PIFR from an inhaler is to use a surrogate measure of flow
through a Clement-Clarke In-Check Dial. Some studies
have used the Clement- Clarke In-Check Dial to study
groups of patients with COPD and asthma. This device
mimics the resitance of the common DPIs and MDIs and
is a surrogate measure of the flow rate an individual
achieves from an inhaler (Chrystyn 2003).
One such study compared the accuracy of the In-
Check Dial versus Inhalation Profile Recordings from
the Diskus™ inhaler in a group of patients with asthma
and COPD; the difference between Diskus™_In Check
and PIF_ Diskus™ was 3.9 (11.9) L/min (Broeders et al.
2003). The margin of error around the absolute differ-
ence is relatively large. Furthermore, not all clinicians
have ready access to an In-Check Dial, especially in
underdeveloped countries.
An alternative approach is to use lung function mea-
sures obtained from baseline spirometry to guide deci-
sions about starting or stopping a DPI. Most patients
with obstructive airways disease will have lung function
tests performed at least once during the course of their
disease. Some authors claim that there is a poor correl-
ation between Diskus™ PIFR and baseline lung function.
Plavec et al. concluded that spirometry is not to be used
for selection of the device for drug application and In-
check Dial should be used instead (Plavec et al. 2012).
However, these studies only investigated the correlation
between Diskus™ PIFR and FEV1 or PEFR.
Intuitively, there should be a relationship between spi-
rometric PIFR and Diskus™ PIFR. This relationship has
not been explored in the prior research. In this study, we
hypothesized that there is a linear relationship between
spirometric PIFR and Diskus™ PIFR. We also hypothe-
sized that the mean spirometric and Diskus™ PIFR from
a group of patients with COPD or Neuromuscular dis-
ease would be significantly lower than healthy volunteers
or patients with asthma. Finally, we hypothesized that
the mean spirometric and Diskus™ IVC from patientswith Asthma, COPD and Neuromuscular Disease would
be lower than healthy subjects or patients with non-
respiratory disorders.
Methods
Eighty-five subjects from a population of healthy volun-
teers and patients with asthma, COPD, neuromuscular
disease and non-respiratory disorders were recruited by
clustered and stratified sampling. Patients were recruited
from different clinics in Beaumont Hospital in Dublin,
Ireland. There were no specific exclusion criteria for this
study apart from capacity to comply with instructions.
Informed consent was obtained for the study with expla-
nations of the study protocol.
This study was approved by the local Hospital Ethics
Committee (ERC/ IRB 13/36) and was performed in ac-
cordance with the ethical standards laid down in the
2000 Declaration of Helsinki. All participants gave their
informed consent prior to their inclusion in the study.
Demographics and baseline lung function by spirom-
etry were recorded (Table 1). Baseline lung function was
taken as the best of three trials. Documented parameters
included Forced expiratory volume in 1 second (FEV1),
Forced Vital Capacity (FVC), FEV1/FVC, Forced inspira-
tory vital capacity (FIVC) and Peak inspiratory flow rate
(PIFR).
Flow and volume readings were taken while patients
used a Diskus™ DPI. The construction of the airtight
container with the Diskus™ inhaler, spirometer connec-
tion and Fleish Pneumotachograph 6800 spirometer
used in this study are shown in Figure 1. Patients were
instructed to exhale gently to functional residual cap-
acity and then inhale at maximal flow rate and duration.
Each patient performed this manoeuvre until two con-
secutive PIFR readings were within 20% of each other.
Values for Inspiratory vital capacity and peak inspiratory
flow rate from the Diskus™ were obtained.
Statistical analysis was done using Audacity v2.0.5.,
MATLAB v9 and IBM SPSS v21. Ordinary least squares
regression of spirometric PIFR versus Diskus™ PIFR was
performed to determine the degree of correlation be-
tween baseline spirometry and flow or volume inhaled
while using the Diskus™ DPI. A stepwise deletion linear
regression was also performed to determine the relation-
ship between Diskus™ PIFR and the independent vari-
ables: condition (categorical), age, gender (categorical),
height, weight, BMI, FEV1, FVC, FEV1/FVC, spirometric
PIFR and spirometric IVC with a significance level for
removal from the model of 0.05.
Subjects were classified into subgroups of Healthy/ Non-
respiratory illness, Asthma, COPD/ Alpha-1-antitrypsin
deficiency, and Neuromuscular Disease. Subgroup analyses
were performed for baseline spirometry and Diskus™ spir-
ometry. Multiple t-tests were done to compare the means
Table 1 Mean values for spirometric and DiskusTM PIFR or IVC according to patient disease group
Diskus™ PIFR Spirometric PIFR Diskus™ IVC Spirometric IVC
Healthy/ Non-respiratory condition 64.57 ± 25.12 247.87 ± 104.35 2.69 ± 1.24 3.37 ± 1.16
(20–97) (59–456) (0.27-4.92) (1.02-5.42)
Asthma 61.56 ± 22.15 209.41 ± 83.26 1.94 ± 0.70 2.42 ± 0.73
(17–102) (59–415) (0.60-3.37) (1.17-3.78)
COPD 49.37 ± 15.68 143.46 ± 62.98 1.86 ± 0.80 2.13 ± 0.79
(22–83) (55–275) (0.36-3.34) (0.71-3.59)
Neuromuscular disease 41.83 ± 24.03 97.53 ± 33.54 1.24 ± 1.13 1.46 ± 1.19
(10–88) (55–153) (0.33-3.87) (0.42-4.13)
Seheult et al. SpringerPlus 2014, 3:496 Page 3 of 7
http://www.springerplus.com/content/3/1/496for spirometric PIFR, Diskus™ PIFR, spirometric IVC and
Diskus™ IC for each group. The proportion of patients in
each category with a flow rate < 60 L/min and/ or an in-
spiratory volume < 1 L was also compared. Patients of age
greater than or equal to fifty years old and less than fifty
years were also compared in the same way.
Results
Approximately two thirds of our recruited patients had a
diagnosis of obstructive airways disease (32% asthma
and 32% COPD). Twenty seven percent were either
healthy or had a non-respiratory condition. Additional
file 1: Table S1 shows the demographics and baseline
lung function parameters for the subjects and Table 1
shows the mean, standard deviation and range for the
spirometric and Diskus™ PIFR and IVC by disease group.
Figure 2 shows the mean spirometric PIFR and 95% con-
fidence interval for the 4 groups of patients studied. The
p values obtained from the one-sided independent sam-
ples t-test for the mean differences between groups areFigure 1 Apparatus used to measure PIFR and IVC from Diskus™ inha
connection to a Fleisch pneumotachograph spirometer.shown in Table 2(a). The mean spirometric PIFR was
significantly lower for the COPD and Neuromuscular
disease groups compared to the Asthma or Healthy/
Non-respiratory condition groups (p ≤ 0.001). These
trends were also seen for mean Diskus™ PIFR values
(Figure 2(b) and Table 2). Additionally, the mean spiro-
metric PIFR for the Neuromuscular Disease group was sig-
nificantly lower than that for the COPD group (p = 0.005).
The Diskus™ PIFR for the COPD and Neuromuscular Dis-
ease groups was more than 10 L/min lower than the
Healthy or Asthma groups and was significantly lower than
60 L/min (p < 0.05). The proportions of patients in each
group with a Diskus™ PIFR < 60 L/min (the threshold for
optimum drug delivery from the Diskus™ inhaler) were sig-
nificantly different (Additional file 1: Table S2).
The mean spirometric and Diskus™ IVC values with
95% CIs and the p-values for differences between group
means are shown in Figures 2(c) and (d) and Tables 1
and 2. The mean spirometric and Diskus™ IVC of the
Healthy group was significantly (>0.75 L) higher thanler. Inhaler is sealed inside airtight container with an aperture for
Figure 2 Mean and 95% Confidence Interval plots for (a) spirometric PIFR versus patient disease group; (b) Diskus™ PIFR versus
patient disease group; (c) spirometric IVC versus patient disease group; and (d) DiskusTM IVC versus patient disease group.
NRC: Non-respiratory condition, NMD: Neuromuscular disease.
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metric PIFR; p = 0.004 for Diskus™ PIFR). The spiromet-
ric IVC was also higher for the Asthma and COPD
groups compared to the Neuromuscular Disease group;
the differences were not statistically significant except
for the spirometric IVC from the Asthma group com-
pared to the Neuromuscular Disease group (p = 0.03).
The p-values for two-sided independent samples t-tests
for age groups, BMI groups and Gender groups are shownTable 2 p values for one-sided independent samples t-tests fo
between patient disease groups





Neuromuscular disease 0.000 (s)





Neuromuscular disease 0.001 (s)
(s) represensts spirometric values and (d) represents DiskusTM values. NS: not signifiin Table 3. The mean values for all four measured flow
rate and volume parameters were significantly higher in
younger patients (age <50 years). There was no difference
between the obese (BMI >30 kg/m2) versus non-obese
groups nor the male versus female groups.
The stepwise deletion regression showed that gender,
height, weight, BMI, FEV1, FVC and FEV1/FVC were not
significantly correlated with Diskus™ PIFR at a significance
level of 0.05. Diskus™ PIFR was moderately correlated withr comparisons of spirometric and Diskus™ PIFR and IVC
IFR)
ition Asthma COPD Neuromuscular disease
NS (d) 0.009 (d) 0.019 (d)
– 0.012 (d) 0.030 (d)
0.001 (s) – NS (d)
0.000 (s) 0.005 (s) –
)
ition Asthma COPD Neuromuscular disease
0.004 (d) 0.004 (d) 0.004 (d)
– NS (d) NS (d)
NS (s) – NS (d)
0.030 (s) NS (s) –
cant at an alpha of 0.05.
Table 3 Mean differences and p values for two-sided







Diskus PIFR 9.61 (0.025) −0.429 (NS) 3.609 (NS)
Baseline PIFR 48.33 (0.017) 23.543 (NS) −2.082 (NS)
Diskus IVC 0.4803 (0.030) 0.2187 (NS) 0.1492 (NS)
Baseline IVC 0.7755 (0.003) 0.8289 (NS) 0.0646 (NS)
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and the relationship is described by the following equation:
PIFRDiskus ¼ 0:139  PIFRSpirometric −0:257
 Age þ 47:696 ð1Þ
pcPIFRSpirometric : p < 0:0001; η
2 ¼ 0:33661068;
Age : p ¼ 0:019; η2 ¼ 0:03651985
While Diskus™ PIFR from COPD and Neuromuscular
disease patients was significantly different to that from
healthy patients and asthmatics, this effect was modified
by both age and spirometric PIFR in the stepwise regres-
sion and as a result, condition was no longer significant in
the model. A scatterplot of Diskus™ PIFR versus spiromet-
ric PIFR with the line of best fit are shown in Figure 3.
Diskus™ PIFR was binned according to a threshold
of 60 L/min and a ROC Curve of Spirometric PIFR ver-
sus Diskus™ PIFR category had an area under the curveFigure 3 Scatterplot of Diskus™ PIFR versus spirometric PIFR showing
(minimum required) and 60 L/min (optimal PIFR for drug delivery). Patients
powder inhaler.of 0.89. At a spirometric PIFR cutoff of 196 L/min, 84%
of Diskus™ PIFR values were correctly classified as ei-
ther greater than or equal to 60 L/min or less than
60 L/min (sensitivity of 79% and specificity of 87%).
When the Diskus™ PIFR was binned according to
a threshold of 30 L/min, a spirometric cutoff of 115
L/min had a sensitivity of 86% and a specificity of 83%
(86% correctly classified). The ROC Curves for a Diskus™
threshold of 60 L/min 30 L/min is shown in Additional
file 1: Figures S1 and S2.
Discussion
Our results show that patients with COPD and Neuromus-
cular Disease do not generate as high a PIFR (spirometric
or through Diskus™) as Healthy subjects, Asthmatics or pa-
tients with non-respiratory conditions. Healthy subjects
also have a significantly higher spirometric and Diskus™
IVC compared to patients with respiratory-related dis-
eases. Numerous authors have shown that drug delivery
from a Diskus™ DPI is dependent on the PIFR of inhal-
ation and that ideally, the PIFR should be above 60 L/min
for optimum Fine Particle delivery. It is clear that the
decision to start a patient on an inhaled medication de-
livered via a DiskusTM DPI should take into account the
age of the patient and the underlying disease. It is likely
that the differences seen between the PIFR of asthmatics
versus COPD patients is explained by the fact that the
COPD patients who were recruited for this study were
older than the patients in the other groups. The lower
PIFR in the patients with Neuromuscular Disease is
most likely explained by the pathophysiology of theirline of best fit. Dashed lines represent Diskus PIFR of 30 L/min
with a Diskus PIFR less than 30 L/min are unsuitable for this dry
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tion and contraction.
The second aim of our study was to show that the
baseline spirometric PIFR could be used to estimate
whether patients would be suitable for the Diskus™ DPI
based on PIFR criteria. There was a moderate correl-
ation between spirometric and Diskus™ PIFR and the use
of spirometric PIFR was very sensitive and specific for
categorizing the Diskus™ PIFR as either greater than or
equal to 60 L/min or less than 60 L/min. The amount of
variance in Diskus™ PIFR explained by the spirometric
PIFR is much higher than published values for FEV1 or
FVC in the literature. The use of subjective evaluation
of PIFR from a DPI is obviously sub-optimal due to
the high inter- and intra- rater variability. In the absence
of a Clement-Clarke In-Check Dial for estimating
Diskus™ PIFR, we believe that our method allows a much
better estimation of the flow rate of inhalation from the
Diskus™ than subjective assessment.
Spirometric PIFR cutoffs of 196 L/min or 115 mL/min
correlate with a Diskus™ PIFR of 60 L/min (optimal de-
livery) and 30 L/min (minimum required for successful
use), respectively. Our study shows that no patient with
a spirometric PIFR above 196 L/min had a Diskus PIFR
below 30 L/min. We believe that the 196 L/min spiro-
metric cutoff is the more useful of the two in the gen-
eral practice setting. It will identify all patients who are
likely to have the minimal required Diskus™ PIFR of
30 L/min. Any patient with a spirometric PIFR below
196 L/min should have further testing possibly using
the Clement Clark In-check Dial™ or consideration of
an alternate device.
While our study shows that spirometric PIFR can be
used to aid decision making regarding suitability of a pa-
tient for a Diskus™ DPI, it is likely that the same rela-
tionship exists for other dry powder devices that are also
flow-rate dependent. However, without studying these
devices, we are unable to make any suggestions regard-
ing cutoffs for other DPIs. Each device has a different in-
trinsic resistance; the Turbohaler™ for instance is even
more peak flow dependent than the Diskus™. We plan to
study these devices in the future but since it is our local
experience that the Diskus is the most popular DPI, we
decided to focus this pilot study on this device.
Based on the stepwise deletion regression, it is clear
that Diskus™ PIFR is related to both spirometric PIFR
and to age. Interestingly, condition was not a significant
variable in this model and it is likely that the differences
in Diskus™ PIFR seen among diseases is explained by the
differences in mean age across the groups. As expected,
COPD patients were older than the other groups and
had lower PIFRs than asthmatics and healthy patients.
Since these three groups were the largest in this study,
it is clear why Diskus™ PIFR is also related to age. Ageshould therefore be taken into account when making a
decision about suitability for a Diskus™ DPI.
Our study has a few mentionable limitations. Technical
issues related to the rig used to measure Diskus™ PIFR
and IVC have been documented previously (Holmes et al.
2013). More importantly, our method for estimation of
Diskus™ PIFR is not perfect (we could not explain about
40% of the variance seen in Diskus™ PIFR by using spiro-
metric PIFR). PIFR is a very effort-dependent measure
and variations in effort exerted by the patient could
explain the differences seen in spirometric and Diskus™
PIFR values. Finally, the need to assess PIFR from a DPI
is important for traditional DPIs for which drug delivery
is flow-rate dependent but may be unnecessary in the
future when the use of modern, sophistically engineered
dry powder formulations and devices becomes more
widespread.
Patients with COPD and Neuromuscular Disease may
not obtain the same drug delivery from a Diskus™ DPI
compared to patients with Asthma and inhaler tech-
nique training for these groups needs to focus on the
flow rate generated during inhaler use. We propose the
use of spirometric PIFR to estimate the PIFR generated
during use of the Diskus™ inhaler in order to guide de-
vice selection and technique training.Conclusion
Patients with COPD and Neuromuscular Disease have a
lower spirometric PIFR and PIFR from a Diskus™ DPI
than healthy subjects or patients with Asthma. Measure-
ment of spirometric PIFR can be used as a surrogate to
estimate the PIFR a patient is likely to generate while
using the Diskus™ DPI. A spirometric PIFR of less than
196 L/min should prompt further investigation into the
suitability of a patient for a Diskus™ DPI, with possible
consideration of alternate devices. Patient age should
also be considered when selecting this common dry
powder inhaler.Additional file
Additional file 1: Table S1. Demographics and baseline lung function
tests for patients by disease category. Table S2. Number of patients in
each disease group with a DiskusTM PIFR greater than or equal to 60 L/
min and less than 60 L/min. Results from Chi-squared test are shown.
The null hypothesis is that the proportions of patients with a Diskus™ PIF
value less than or equal to sixty is independent of their diagnosis.As
the test statistic is greater than the critical value, we can reject the null
hypothesis. Figure S1. Receiver Operating Characteristic Curve for
spirometric PIFR versus binary Diskus™ PIFR based on threshold of 60 L/min.
The solid line represents an AUC of 0.5. Figure S2. Receiver Operating
Characteristic Curve for spirometric PIFR versus binary Diskus™ PIFR based
on threshold of 30 L/min. The solid line represents an AUC of 0.5.
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